J&J clears PhII for rare blood dis­or­der with drug from $6.5B Mo­men­ta buy­out

The lead drug from John­son & John­son’s $6.5 bil­lion buy­out of Mo­men­ta, now be­ing test­ed in near­ly 10 in­di­ca­tions, has cleared a Phase II in a rare blood dis­or­der.

J&J’s ther­a­peu­tics unit Janssen was sparse on de­tails but said the drug, nipocal­imab, met the pri­ma­ry end­point in the UNI­TY study. The ma­jor­i­ty of preg­nant pa­tients in the tri­al ex­pe­ri­enced a live birth at or af­ter 32 weeks with­out re­quir­ing in­trauter­ine trans­fu­sion, or IUT, the Big Phar­ma said on Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.